Summit Therapeutics (SMMT) Total Liabilities (2017 - 2026)

Summit Therapeutics (SMMT) has reported Total Liabilities for 10 consecutive years, with $122.2 million the latest figure, recorded in Q2 2026.

• Quarterly Total Liabilities rose 89.17% year-over-year to $122.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $122.2 million (up 89.17% YoY) and the FY2025 annual result came in at $92.3 million, up 97.22% from the prior year.
• Total Liabilities advanced to $122.2 million in Q2 2026 per SMMT's latest filing, from $101.9 million in the prior quarter.
• Over the last five years, Total Liabilities for SMMT reached as high as $537.5 million in Q4 2022 and fell as low as $22.1 million in Q3 2022.
• A 5-year average of $112.3 million and a median of $97.1 million in 2025 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2022 — Total Liabilities jumped 1686.35% — and 2023, when it sank 76.7%.
• Year by year, Total Liabilities stood at $537.5 million in 2022, then plunged by 76.7% to $125.3 million in 2023, then sank by 62.63% to $46.8 million in 2024, then soared by 97.22% to $92.3 million in 2025, then soared by 32.36% to $122.2 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $122.2 million, $101.9 million, and $92.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.